Brandon Valantine, DO
Interventional Pain Medicine · Oklahoma City, OKNPI 1558717553
Payments from drug & device makers
What this record shows
Medtronic accounts for 73.0% of it on its own, with 11 other manufacturers making up the rest. Among interventional pain medicine clinicians in OK with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 113 payments — averaging $82.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$7K
- Relievant Medsystems, Inc.$1K
- Boston Scientific$797
- Nalu Medical, Inc.$361
- Averitas Pharma Inc.$118
- Nevro Corp.$93
- plus $155 from 6 others
What the payments were for
- Travel & lodging$5,55059%
- Food & beverage$3,82841%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 84 | $6,842 |
| Relievant Medsystems, Inc. | 6 | $1,013 |
| Boston Scientific | 10 | $797 |
| Nalu Medical, Inc. | 3 | $361 |
| Averitas Pharma Inc. | 2 | $118 |
| Nevro Corp. | 1 | $93 |
| Stryker | 2 | $54 |
| Pacira Pharmaceuticals Incorporated | 1 | $25 |
| Convatec Inc. | 1 | $25 |
| Baxter Healthcare | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $18 |
| SPR Therapeutics, Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,378 in reported general payments places this provider in the 95th percentile of 27 interventional pain medicine providers in Oklahoma.
See all interventional pain medicine providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Celecoxib | 39 | $747 |
| Pregabalin | 40 | $552 |
| Gabapentin | 41 | $493 |
| Methylprednisolone | 29 | $212 |
| Cyclobenzaprine Hcl | 19 | $174 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 18 | $160 |
| Baclofen | 11 | $135 |
| Tramadol Hcl | 28 | $86 |
| Meloxicam | 12 | $66 |
Paid to pharmacies, not to this prescriber.
Other interventional pain medicine in Oklahoma City
- Justin PorterOklahoma City$8K
- Blake ChristensenOklahoma City$6K
- Shawn EllisOklahoma City$6K
- Nathan OverbeyOklahoma City$5K
- Ahmed AmayemOklahoma City$5K
- Peyton JohnsonOklahoma City$5K
- Patrick PrevoOklahoma City$4K
- Arthur BeachamOklahoma City$4K
- Timothy CramerOklahoma City$3K
- Sanaa KarimOklahoma City$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.